Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 5/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15568552 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| Hydrochloric Acid SCHEMBL15568677 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| Hydrochloric Acid SCHEMBL15568465 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| Hydrochloric Acid SCHEMBL15568727 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| Hydrochloric Acid SCHEMBL15568532 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| Hydrochloric Acid SCHEMBL15796583 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL15796587 | 0.98 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL15796319 | 0.98 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL453610 | 0.98 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL15305326 | 0.98 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119367454-B | Cupping spray and preparation method thereof | 山东威阳医疗器械科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119367454-A | Cupping spray and preparation method thereof | 山东威阳医疗器械科技有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-115920457-A | Fluorine-containing polyether organic silicon defoaming agent and preparation method thereof | 广东南辉新材料有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115518418-A | Mineral oil defoaming agent and preparation method thereof | 广东南辉新材料有限公司 | 2022-12-27 | — | — | CN | claimed |
| US-20160220524-A1 | COMPOSITIONS OF SMALL MOLECULE THERAPEUTICS | NEXMED HOLDINGS, INC. | 2016-08-04 | — | — | US | claimed |
| US-20150265709-A1 | THERAPEUTIC PEPTIDE COMPOSITIONS AND METHODS | NEXMED HOLDINGS, INC. (US) | 2015-09-24 | — | — | US | claimed |
| US-8962595-B2 | Compositions of small molecule therapeutics | NEXMED HOLDINGS, INC. (US) | 2015-02-24 | — | — | US | claimed |
| US-20140170207-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | NEXMED HOLDINGS, INC. | 2014-06-19 | — | — | US | claimed |
| US-20130210766-A1 | COMPOSITIONS OF SMALL MOLECULE THERAPEUTICS | NEXMED HOLDINGS, INC. (US) | 2013-08-15 | — | — | US | claimed |
| US-20130209393-A1 | THERAPEUTIC PEPTIDE COMPOSITIONS AND METHODS | NEXMED HOLDINGS, INC. (US) | 2013-08-15 | — | — | US | claimed |
| US-20040131664-A1 | Topical stabilized prostaglandin E compound dosage forms | NEXMED HOLDINGS, INC. | 2004-07-08 | — | — | US | claimed |
| US-20040110843-A1 | Methods of treatment of male erectile dysfunction | NEXMED (HOLDINGS), INC. | 2004-06-10 | — | — | US | claimed |
| WO-2004022064-A1 | METHODS OF TREATMENT OF MALE ERECTILE DYSFUNCTION | NEXMED (HOLDINGS), INC. (US) | 2004-03-18 | — | — | WO | claimed |
| EP-1278495-A1 | TOPICAL COMPOSITIONS CONTAINING PROSTAGLANDIN E 1? | Nexmed Holdings, Inc. (US) | 2003-01-29 | — | — | EP | claimed |
| EP-1097126-A4 | CRYSTALLINE SALTS OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE | NEXMED HOLDINGS INC (US) | 2002-08-28 | — | — | EP | claimed |
| US-6414028-B1 | MIXTURE WITH SKIN PENETRATION INTENSIFIER, POLYSACCHARIDE GUM AND BUFFER | NEXMED HOLDINGS, INC. | 2002-07-02 | — | — | US | claimed |
| WO-2001074279-A1 | TOPICAL COMPOSITIONS CONTAINING PROSTAGLANDIN E¿1? | NEXMED HOLDINGS, INC. (US) | 2001-10-11 | — | — | WO | claimed |
| EP-1097126-A1 | CRYSTALLINE SALTS OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE | Nexmed Holdings, Inc. (US) | 2001-05-09 | — | — | EP | claimed |
| WO-2000069809-A1 | CRYSTALLINE SALTS OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE | NEXMED HOLDINGS, INC. (US) | 2000-11-23 | — | — | WO | claimed |
| US-6118020-A | SALT FORMATION, PRECIPITATION, TRANSDERMAL DRUG DELIVERY PENETRATION AGENT | NEXMED HOLDINGS, INC. (US) | 2000-09-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130209393-A1 | THERAPEUTIC PEPTIDE COMPOSITIONS AND METHODS | IAPP, VIP, NGLY1 | ACHE 4250/4885NAAA 562/4885EPHX1 4826/4885 |
| US-20040131664-A1 | Topical stabilized prostaglandin E compound dosage forms | PTGES, PTGER1, PTGES2 | ACHE 2000/4885NAAA 2770/4885EPHX1 113/4885 |
| US-20140170207-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | CLPP, POLR1C, NACA | ACHE 3324/4885NAAA 189/4885EPHX1 3515/4885 |
| US-20150265709-A1 | THERAPEUTIC PEPTIDE COMPOSITIONS AND METHODS | IAPP, VIP, NGLY1 | ACHE 4250/4885NAAA 562/4885EPHX1 4826/4885 |
| US-20040110843-A1 | Methods of treatment of male erectile dysfunction | PDE3A, PDE3B, PDE2A | ACHE 343/4885NAAA 868/4885EPHX1 489/4885 |
| US-20160220524-A1 | COMPOSITIONS OF SMALL MOLECULE THERAPEUTICS | SLC43A1, SLC7A5, SLC1A5 | ACHE 3683/4885NAAA 881/4885EPHX1 3954/4885 |
| US-20130210766-A1 | COMPOSITIONS OF SMALL MOLECULE THERAPEUTICS | SLC43A1, SLC7A5, SLC1A5 | ACHE 3683/4885NAAA 881/4885EPHX1 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.